Johnson & Johnson reported Q4 2025 revenues of $24.56 billion, beating expectations, and forecasted 2026 sales between $99.5 billion and $100.5 billion13.
J&J signed a voluntary Most-Favored-Nation (MFN) pricing agreement with the Trump administration, offering discounted prices on select medicines via TrumpRx.gov in exchange for tariff exemptions1245.
The 2026 guidance accounts for 'hundreds of millions' in revenue impact from the MFN deal, offset by elimination of PBM rebates and tariff breaks, with growth driven by MedTech and Innovative Medicine123.
J&J is investing $55 billion in U.S. manufacturing, including new facilities in Pennsylvania and North Carolina for cell therapies and drug products34.
Despite challenges like the 'Stelara cliff' from biosimilar competition, J&J anticipates crossing the $100 billion annual revenue threshold as the first healthcare-exclusive company13.
Sources:
1. http://markets.chroniclejournal.com/chroniclejournal/article/marketminute-2026-1-21-j-and-j-forecasts-100-billion-milestone-for-2026-as-trump-drug-pricing-deals-reshape-the-pharma-landscape
2. https://www.marketscreener.com/news/j-j-cfo-says-2026-guidance-includes-hundreds-of-millions-of-dollars-impact-from-mfn-deal-with-trum-ce7e58ddd18df426
3. http://business.times-online.com/times-online/article/marketminute-2026-1-21-j-and-j-forecasts-100-billion-milestone-for-2026-as-trump-drug-pricing-deals-reshape-the-pharma-landscape
4. https://www.pharmaceutical-technology.com/news/johnson-johnson-mfn-drug-pricing-deal-branded-medicines/
5. https://www.bioworld.com/articles/727774-two-to-go-j-and-j-the-latest-pharma-to-reach-mfn-drug-pricing-deal